Healthcare and Life Science
Glox Therapeutics awarded £1M PACE grant to accelerate development of precision antibiotics against antimicrobial-resistant pathogens
Novel therapeutics to address unmet clinical need for pneumonias caused by drug-resistant Escherichia coli and Klebsiella pneumoniae PACE provides funding and support for innovative, high value, high risk, early phase drug discovery and diagnostic projects Glasgow, UK, 20 November...
COPD management: a critical look at gaps in pharmaceutical innovation
Chronic Obstructive Pulmonary Disease (COPD) presents a major global health challenge, marked by chronic respiratory decline and frequent exacerbations. Despite advances in treatment, comprehensive management strategies remain limited, revealing significant gaps in patient care. ...
CrestOptics and Tomocube partner to advance 3D imaging with new multimodal imaging platform
First commercially available spinning-disk confocal holotomographic instrument, enabling advanced 3D imaging with fluorescence-based detection New system showcased at SPAOM24 (20th-22nd November, Toledo, Spain) Rome, IT, 20 November, 2024: CrestOptics S.p.A., a manufacturer of high...
Tagomics announces a multiomic profiling co-marketing agreement with Agilent
Exclusive program will provide customers with a single, unified workflow for comprehensive genomic profiling and genome-wide epigenetic analysis ...
Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line
Strategic agreement will accelerate the manufacturing of fully human multispecific therapies for chronic retinal diseases with high unmet need using Asimov’s CHO Edge System ...
Steritas announces collaboration with argenx to advance evidence for novel steroid-sparing therapeutics
First-in-class steroid-toxicity outcome assessments licensed by argenx to support development of novel steroid-sparing therapeutics for autoimmune diseases Boston, MA, USA, 19 November 2024: Steritas LLC., a company dedicated to enhancing care for steroid-treated patients, announces a ...
Enterprise Therapeutics publishes on medicinal chemistry of ETD001, a novel inhaled ENaC blocker for treatment of cystic fibrosis
Paper in the European Journal of Medicinal Chemistry discloses the optimisation process leading to the selection for development of ETD001, an inhaled ENaC blocker with a best-in-class profile ETD001 commenced Phase 2 clinical study in people with cystic fibrosis in July 2024 Brig...
The importance of choosing sustainable accommodation for winter travel
Winter is a time for cosy getaways, snowy adventures, and festive experiences, but it’s also a season that puts added pressure on the environment. Increased energy use for heating, high water demand, and waste generation can make winter travel a challenging time to be eco-friendly. One ...
Sapio Sciences collaborates with Waters Corporation to improve efficiency of laboratory operations
The advanced connectivity of Sapio LIMS with waters_connect for Quantitation liquid chromatography mass spectrometry (LC-MS) software Baltimore, MD, 18 November 2024 – Sapio Sciences, the science-aware™ lab informatics platform, announces it has entered a co-marketing agreement with Wa...
Mursla Bio’s EvoLiver surpasses current standards in liver cancer surveillance, data presented at AASLD Liver Meeting 2024
EvoLiver™ demonstrated 86% early-stage sensitivity at 88% specificity for liver cancer surveillance among cirrhotic, high-risk patients with diverse etiologies Validates clinical value of multi-omics content in organ-specific extracellular vesicles for liver cancer detection Data pr...